New market study, "Mylan Inc.: PharmaVitae Profile", has been published

May 17, 2011 - PRLog -- Introduction

The analysis examines the historical and forecast performance for Mylan in the generic prescription pharmaceutical sector.  The profile encompasses global company strategy and assessment of financial performance.
Features and benefits

* Gain insight in to Mylan's stategic outlook across the next 6 years.* Analyze company sales forecasts by therapy area, geography and formulation.

Highlights

Strategic insight into the prospects for Mylan over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales
Your key questions answered

* Benchmark Mylan's performance against key rivals in the generic prescription pharmaceutical sector.* See how the acquisition of Merck KGaA's generics unit continues to re-shape Mylan's business

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/158622_mylan_inc_pharmavitae_p...
------------------------------------------------------------


Report Table of Contents:

Executive Summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2005-
Financial performance, 2005-
Mylan: PharmaVitae forecasts at a glance
Strategic insight
Impact of M&A over 2003-
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Quarterly update
Company introduction
Company sales
Company financials
Key products
Data sourcing
Analyst consensus
QUARTERLY NEWS UPDATE
Latest quarterly sales
Latest prescription pharma product news
Q3
Q2
Q1
Latest corporate news
Q3
Q2
Q1
Q4
Q3
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
M&A history
Early M&A boosts branded Prescription pharmaceuticals capacity
Matrix acquisition provides API capabilities
Acquisition of Merck Generics
Mylan- potential for further M&A?
Current corporate structure
Generics Segment
Specialty Segment
Matrix Segment
COMPANY SALES
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2009-
Branded and generic portfolio sales analysis
Therapy area analysis
Geographic analysis
Formulation analysis
COMPANY FINANCIALS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003-
Operating costs and profit analysis
Operating costs and profit analysis, 2003-
OPERATING COST RATIO AND PROFIT MARGIN ANALYSIS, 2003-
Operating cost ratio and profit margin analysis, 2009-
Operating costs and profit analysis, 2009-
KEY BRANDED PRODUCTS
Product portfolio
APPENDIX
Abbreviations

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment.  View more research from Datamonitor at http://www.fastmr.com/catalog/publishers.aspx?pubid=1002

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.